Aktis Oncology (NASDAQ:AKTS) reported quarterly earnings results on August 13, 2026 that fell short of analyst expectations.
At publication ·
Aktis Oncology (NASDAQ:AKTS) · earnings miss
At a glance
Aktis Oncology (NASDAQ:AKTS) reported quarterly earnings results on August 13, 2026 that fell short of analyst expectations.
The Healthcare company reported earnings per share of $-0.44, missing the consensus estimate of $-0.43 by $0.01 per share. Revenue came in at $3.4M, beating the estimate of $2.5M.
Aktis Oncology's stock moved following the earnings release. The stock currently trades at $24.28 with a market capitalization of $1.1B.
Missing analyst estimates puts pressure on a stock as investors reassess their growth assumptions. The market's reaction to an earnings miss depends heavily on the magnitude of the shortfall, the company's forward guidance, and whether the miss was driven by temporary or structural factors.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Aktis Oncology should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.
| Quarter | EPS Actual | EPS Est. | Surprise |
|---|---|---|---|
| Q2 (Aug 2026) | $-0.44 | $-0.43 | -2.3% |
| Q1 (May 2026) | $-0.38 | $-0.33 | -15.2% |
Related Tools: Earnings Calendar | View AKTS Stock Page
Check the latest earnings dates on our AKTS earnings page or the Earnings Calendar.
See the full Q2 results including EPS actual vs estimate on our AKTS earnings page.
Current market data
NASDAQ · AKTS
$23.79
Up: +$1.14 · +4.79%
Live quote updated
Keep reading
